Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PER2 | O15055 | 3/20 | 0.33 |
| ▸ | CRY1 | Q16526 | 3/20 | 0.33 |
| ▸ | CRY2 | Q49AN0 | 3/20 | 0.33 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19766998 | 0.74 | PIK3CD (0.42) | PIK3CDPER2CRY1CRY2VCAM1 | |
| SCHEMBL26323259 | 0.73 | CA1 (0.55) | — | |
| SCHEMBL16451224 | 0.73 | PER2 (0.42) | PIK3CDPER2CRY1CRY2VCAM1 | |
| SCHEMBL7673928 | 0.71 | VCAM1 (0.38) | PIK3CDPER2CRY1CRY2VCAM1 | |
| SCHEMBL13100464 | 0.71 | ALDH1A1 (0.33) | — | |
| SCHEMBL25257892 | 0.71 | VCAM1 (0.35) | PIK3CDPER2CRY1CRY2VCAM1 | |
| SCHEMBL21413190 | 0.71 | MAPK1 (0.35) | PIK3CDPER2CRY1CRY2VCAM1 | |
| SCHEMBL13100465 | 0.70 | TP53 (0.39) | — | |
| SCHEMBL19767020 | 0.70 | PIK3CD (0.33) | PIK3CDVCAM1 | |
| SCHEMBL25456874 | 0.69 | PIK3CD (0.37) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962667-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | Microdose Therapeutix, Inc. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140363395-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | MICRODOSE THERAPEUTX INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-8846735-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140072532-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | MICRODOSE THERAPEUTX, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8575205-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20120183498-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | NITZ THEODORE J (US) | 2012-07-19 | — | — | US | disclosed |
| US-7358250-B2 | Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity | AMGEN INC. (US) | 2008-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140072532-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | TTPA, HAVCR2, ZC3HAV1 | PIK3CD 4366/4885PER2 1110/4885CRY1 239/4885 |
| US-20140363395-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | TTPA, HAVCR2, ZC3HAV1 | PIK3CD 4366/4885PER2 1110/4885CRY1 239/4885 |
| US-20120183498-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | TTPA, HAVCR2, ZC3HAV1 | PIK3CD 4366/4885PER2 1110/4885CRY1 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.